title: Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults.
abstract: Amyloid burden and white matter hyperintensities (WMH) are two common markers of neurodegeneration present in advanced aging. Each represents a potential early indicator of an age-related neurological disorder that impacts cognition. The presence of amyloid is observed in a substantial subset of cognitively normal older adults, but the literature remains equivocal regarding whether amyloid in nondemented populations is deleterious to cognition. Similarly, WMH are detected in many nondemented older adults and there is a body of evidence indicating that WMH are associated with decreased executive function and other cognitive domains. The current study investigated amyloid burden and WMH in clinically normal older adult humans aged 65-86 (N = 168) and examined each biomarker's relation with cognitive domains of episodic memory, executive function, and speed of processing. Factors for each domain were derived from a neuropsychological battery on a theoretical basis without reference to the relation between cognition and the biomarkers. Amyloid burden and WMH were not correlated with one another. Age was associated with lower performance in all cognitive domains, while higher estimated verbal intelligence was associated with higher performance in all domains. Hypothesis-driven tests revealed that amyloid burden and WMH had distinct cognitive profiles, with amyloid burden having a specific influence on episodic memory and WMH primarily associated with executive function but having broad (but lesser) effects on the other domains. These findings suggest that even before clinical impairment, amyloid burden and WMH likely represent neuropathological cascades with distinct etiologies and dissociable influences on cognition.
authors.affiliation: Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA. hedden@nmr.mgh.harvard.edu
authors.forename: Trey
authors.initials: T
authors.lastname: Hedden
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Mormino
authors.forename: Rebecca E
authors.initials: RE
authors.lastname: Amariglio
authors.forename: Alayna P
authors.initials: AP
authors.lastname: Younger
authors.forename: Aaron P
authors.initials: AP
authors.lastname: Schultz
authors.forename: J Alex
authors.initials: JA
authors.lastname: Becker
authors.forename: Randy L
authors.initials: RL
authors.lastname: Buckner
authors.forename: Keith A
authors.initials: KA
authors.lastname: Johnson
authors.forename: Reisa A
authors.initials: RA
authors.lastname: Sperling
authors.forename: Dorene M
authors.initials: DM
authors.lastname: Rentz
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000682:Amyloid / Q000378:metabolism*; D000686:Amyloidosis / Q000000981:diagnostic imaging / Q000378:metabolism*; D019412:Anatomy, Cross-Sectional; D001921:Brain / Q000473:pathology*; D003071:Cognition / Q000502:physiology*; D005163:Factor Analysis, Statistical; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D009483:Neuropsychological Tests; D049268:Positron-Emission Tomography; D011597:Psychomotor Performance / Q000502:physiology
chemical_list: D000682:Amyloid